Skip to main content

Table 1 Patient characteristics at ICU admission according to study group and aspergillosis status based on Blot definition

From: Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study

 

SARS-CoV-2 pneumonia

n = 566

Influenza pneumonia

n = 481

No putative IPA, or colonization

(n = 543)

Aspergillus colonization

(n = 9)

Putative IPA

(n = 14)

No putative IPA, or colonization

(n = 432)

Aspergillus colonization

(n = 20)

Putative IPA

(n = 29)

Age, years

64 (55 to 71)

63 (62 to 68)

67 (52 to 75)

62 (53 to 71)

61 (51 to 71)

58 (52 to 64)

Men

387/543 (71.3)

8/9 (88.9)

11/14 (78.6)

271/432 (62.7)

13/20 (65.0)

14/29 (48.3)

Body mass index, kg/m2

28.7 (25.7 to 33.6)

31.2 (26.5 to 32.5)

29.9 (28.6 to 31.8)

27.7 (23.3 to 32.7)

29.0 (25.7 to 30.4)

25.2 (21.5 to 28.5)

Severity scores

      

SAPS II

41 (32 to 56)

44 (37 to 48)

36 (31 to 48)

50 (39 to 64)

57 (42 to 65)

47 (36 to 63)

SOFA score§

6 (3 to 8)

6 (5 to 9)

5 (4 to 7)

8 (6 to 11)

7 (6 to 10)

7 (4 to 12)

Comorbidities scores

      

McCabe classification

      

Non-fatal

454/518 (87.6)

8/9 (88.9)

11/14 (78.6)

288/410 (70.2)

17/18 (94.4)

19/27 (70.4)

Fatal < 5 years

58/518 (11.2)

1/9 (11.1)

3/14 (21.4)

107/410 (26.1)

1/18 (5.6)

6/27 (22.2)

Fatal < 1 year

6/518 (1.2)

0/9 (0.0)

0/14 (0.0)

15/410 (3.7)

0/18 (0.0)

2/27 (7.4)

Charlson Comorbidity Indexll

3 (1 to 4)

4 (2 to 5)

2.5 (2 to 5)

3 (2 to 5)

4 (2 to 6)

3 (1 to 4)

Chronic diseases

      

Diabetes mellitus

159/540 (29.4)

5/9 (55.6)

4/14 (28.6)

94/425 (22.1)

4/20 (20.0)

6/28 (21.4)

Chronic kidney disease

29/535 (5.4)

3/8 (37.5)

1/14 (7.1)

35/427 (8.2)

1/20 (5.0)

3/27 (11.1)

Heart disease

98/535 (18.3)

2/9 (22.2)

2/14 (14.3)

108/426 (25.4)

3/20 (15.0)

6/29 (20.7)

Chronic heart failure

19/534 (3.6)

2/8 (25.0)

0/14 (0.0)

35/426 (8.2)

1/20 (5.0)

1/28 (3.6)

COPD

35/536 (6.5)

0/8 (0.0)

2/14 (14.3)

119/426 (27.9)

7/20 (35.0)

3/28 (10.7)

Chronic respiratory failure

19/534 (3.6)

0/8 (0.0)

1/14 (7.1)

62/426 (14.6)

2/20 (10.0)

2/28 (7.1)

Cirrhosis

8/535 (1.5)

0/8 (0.0)

0/14 (0.0)

14/426 (3.3)

1/20 (5.0)

1/28 (3.6)

Immunosuppression

46/535 (8.6)

2/8 (25.0)

2/14 (14.3)

93/429 (21.7)

2/20 (10.0)

11/29 (37.9)

Hematological malignancy

5/534 (0.9)

0/8 (0.0)

1/14 (7.1)

24/428 (5.6)

1/20 (5.0)

5/29 (17.2)

Solid cancer

25/534 (4.7)

0/8 (0.0)

0/14 (0.0)

37/428 (8.6)

1/20 (5.0)

1/29 (3.4)

Organ transplant

5/534 (0.9)

1/8 (12.5)

0/14 (0.0)

7/428 (1.6)

0/20 (0.0)

4/29 (13.8)

HIV

3/534 (0.6)

0/8 (0.0)

0/14 (0.0)

5/428 (1.2)

0/20 (0.0)

0/29 (0.0)

Immunosuppressive drugs

21/534 (3.9)

2/8 (25.0)

2/14 (14.3)

44/428 (10.3)

0/20 (0.0)

7/29 (24.1)

Active smoking

29/536 (5.4)

0/8 (0.0)

0/14 (0.0)

130/426 (30.5)

8/20 (40.0)

11/29 (37.9)

Alcohol abuse

33/534 (6.2)

1/8 (12.5)

0/14 (0.0)

75/425 (17.6)

3/20 (15.0)

7/29 (24.1)

Location before ICU admission

      

Home

264/543 (48.6)

3/9 (33.3)

3/14 (21.4)

251/431 (58.2)

8/20 (40.0)

15/29 (51.7)

Hospital ward

199/543 (36.6)

5/9 (55.6)

11/14 (78.6)

138/431 (32.0)

7/20 (35.0)

12/29 (41.4)

Another ICU

80/543 (14.7)

1/9 (11.1)

0/14 (0.0)

42/431 (9.7)

5/20 (25.0)

2/29 (6.9)

Recent hospitalization (< 3 months)

39/541 (7.2)

2/9 (22.2)

3/14 (21.4)

61/429 (14.2)

6/20 (30.0)

5/29 (17.2)

Recent antibiotics (< 3 months)

70/542 (12.9)

1/9 (11.1)

3/14 (21.4)

79/427 (18.5)

8/20 (40.0)

7/29 (24.1)

Hospital to ICU admission, days¥

1 (0 to 2)

1 (0 to 2)

1 (0 to 2)

0 (0 to 1)

1 (0 to 2)

1 (0 to 4)

Hospital admission to intubation, days¤

1 (0 to 3)

2 (1 to 7)

2 (1 to 3)

1 (0 to 2)

1 (0 to 3)

2 (0 to 5)

Antibiotic treatment on ICU admission

475/533 (89.1)

7/9 (77.8)

12/14 (85.7)

369/421 (87.6)

19/20 (95.0)

28/29 (96.6)

Causes for ICU admission

      

Shock

99/534 (18.5)

2/7 (28.6)

1/14 (7.1)

188/423 (44.4)

9/20 (45.0)

13/26 (50.0)

Acute respiratory failure

500/542 (92.3)

8/9 (88.9)

13/14 (92.9)

386/430 (89.8)

18/20 (90.0)

28/29 (96.6)

ARDS

370/538 (68.8)

6/9 (66.7)

8/14 (57.1)

192/422 (45.5)

13/20 (65.0)

15/26 (57.7)

Neurological failure

25/525 (4.8)

1/7 (14.3)

0/14 (0.0)

66/419 (15.8)

1/20 (5.0)

2/25 (8.0)

Cardiac arrest

3/524 (0.6)

0/7 (0.0)

0/14 (0.0)

23/419 (5.5)

0/20 (0.0)

2/25 (8.0)

Acute kidney injury

92/425 (17.5)

2/7 (28.6)

2/14 (14.3)

118/415 (28.4)

6/20 (30.0)

9/25 (36.0)

  1. Values are as n/N (%) or median (interquartile range). 100 missing values (SARS-CoV-2, n = 32; influenza, n = 68); 64 missing values (SARS-CoV-2, n = 43; influenza, n = 21); §25 missing values (SARS-CoV-2, n = 21; influenza, n = 4); ll30 missing values (SARS-CoV-2, n = 19; influenza, n = 11); ¥59 missing values (SARS-CoV-2, n = 31; influenza, n = 28); ¤ 75 missing values (SARS-CoV-2, n = 42; influenza, n = 33)
  2. McCabe classification of comorbidities and likelihood of survival, likely to survive > 5 years, 1–5 years, < 1 year; Chronic kidney disease, KDOQI CKD classification stage 4 or 5 (creatinine clearance < 30 ml/mn); Chronic heart failure, NYHA class III or IV; Heart disease, ischemic heart disease or atrial fibrillation; Cirrhosis, Child–Pugh score B or C; antibiotic treatment on ICU admission, at least one dose of antibiotics in the first day of ICU stay; More than one cause for ICU admission is possible
  3. ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit, SAPS II, simplified acute physiology score II; SOFA, sequential organ failure assessment